iPSC Biobank of Biomarkers Diversity in Cardiovascular Disease
- Conditions
- Heart FailureCongenital Heart DiseaseCardiometabolic SyndromeCardiovascular DiseasesArrythmiaCardiomyopathiesCerebrovascular Accident
- Registration Number
- NCT06371937
- Lead Sponsor
- Lawson Health Research Institute
- Brief Summary
The Investigators will create a clinical database and a Biobank of stem cells derived from the blood of participants with cardiovascular disease. The Investigators will recruit participants from diverse racial and ethnic backgrounds with equal representation from both sexes. The Investigators expect to create stem cells and analyze the blood for protein biomarkers and genetic causes of cardiovascular disease. The stem cell biobank and clinical data will be a powerful tool for studying cardiovascular disease.
- Detailed Description
Cardiovascular disease is the leading cause of morbidity and mortality. The development of cardiovascular disease includes both genetic and epigenetic factors. Understanding their molecular and cellular mechanism is necessary to identify novel drug targets and treat the disease. Present in vitro and in vivo models of the disease do not mimic human pathophysiology, and obtaining the primary cells from the patients for the studies relevant to the cardiovascular and pulmonary system is difficult. Induced pluripotent stem cells (iPSCs) are derived from a person's blood cells and facilitate the discovery of cardiovascular disease mechanisms. The Investigators propose recruiting cardiovascular patients from diverse ethnic backgrounds and creating a rich clinical database using REDCap. Blood samples will be obtained from participants and used to create iPSCs. The participant will have DNA sequencing, and serum will be analyzed for protein biomarkers. The multi-omics data and reprogrammed iPSCs will be stored in the Cardiology and Critical Care (C3RP) laboratory at the Robarts Research Institute at Western University. The reprogrammed iPSCs can generate a limitless supply of cardiovascular tissue. Moreover, the iPSC-derived data will be correlated with clinical information, genetic sequencing, and protein biomarkers from serum analysis. The Investigators expect to create an iPSC biobank coupled with a rich clinical dataset, including genetic sequencing analysis and protein biomarkers that will enable the discovery of novel biomarkers and drug targets for cardiovascular disease.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Adult (18 to 80 years of age)
- Cardiovascular Disease (CVD)
- Cerebrovascular Disease (CBD)
- Peripheral Vascular Disease (PVD)
- Inherited Arrhythmias
- Cardiomyopathies
- Congenital Heart Disease (CHD)
- Aortopathy
- Hypertension
- Cardiometabolic Disease (CMD)
- Younger than 18 years of age.
- Patients not able to provide consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method REDCap Database 10 years Identify patients with cardiovascular disease from ethnically diverse backgrounds and create a clinical database with REDCap.
Molecular profiling of participants 10 years Molecular profiling of iPSC-derived tissue and patient serum using microarray, DNA sequencing, and high throughput "omics" technologies (transcriptomic analysis, proteomic analysis, metabolomic studies, and functional assays).
Induced pluripotent stem cell (iPSC) Biobank 10 years Reprogram peripheral blood mononuclear cells (PBMC) to iPSCs.
Differentiation into Cardiovascular lineages 10 years Differentiate of iPSCs into different cardiovascular lineages (endothelial cells, smooth muscle cells, cardiomyocytes, etc.)
Bioinformatics analysis 10 years Bioinformatics analysis of clinical, iPSC disease modeling, and serum omics analysis.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
London Regional Health Science Centre
🇨🇦London, Ontario, Canada